

Please cancel claims 125, 141 and 161, without prejudice.


### REMARKS

Claims 88-90, 94, 118-120, 124, 135, 137-140, 142, 150, 152, 154-157, 160, 165-171, and 175-177 were previously allowed. Claim 161 was objected to. The remaining claims were rejected based upon the recitation of SEQ ID NO.:10 in the independent claims 117, 121 and 153. These claims have been amended and should now be allowable. Claims 125, 141 and 161 have been canceled. With these amendments, dependent claims 122-123, 126-134, 143-149, 158 and 172-174 should similarly be allowable.

For the foregoing reasons and in view of the amendments, Applicants respectfully request entry of the amendments and withdrawal of the outstanding rejections. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining questions and facilitate the prosecution and allowance of the application or to place the case in better form for appeal.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,



Daniel R. Curry  
Attorney for Applicants  
Registration No: 32,727  
Phone: (805) 447-8102  
Date: August 15, 2000

Please send all future correspondence to:

U.S. Patent Operations/DRC  
Dept. 4300 M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799